APA (7th ed.) Citation

F, B., BH, O., S, S., FS, O., TJ, Z., D, N., . . . V, H. (2025). Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance). European journal of cancer (Oxford, England : 1990), 227, 115694. https://doi.org/10.1016/j.ejca.2025.115694

Chicago Style (17th ed.) Citation

F, Battaglin, et al. "Outcomes for FOLFIRI Plus Bevacizumab or Cetuximab in Patients Treated with Oxaliplatin-based Adjuvant Therapy: A Combined Analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance)." European Journal of Cancer (Oxford, England : 1990) 227 (2025): 115694. https://doi.org/10.1016/j.ejca.2025.115694.

MLA (9th ed.) Citation

F, Battaglin, et al. "Outcomes for FOLFIRI Plus Bevacizumab or Cetuximab in Patients Treated with Oxaliplatin-based Adjuvant Therapy: A Combined Analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance)." European Journal of Cancer (Oxford, England : 1990), vol. 227, 2025, p. 115694, https://doi.org/10.1016/j.ejca.2025.115694.